The Claim
In adults with type 2 diabetes, administration of liraglutide at doses of 1.2 mg and 1.8 mg per day significantly delays gastric emptying during the first hour after a meal, contributing to reduced postprandial glucose excursions, while a dose of 0.6 mg per day does not produce a statistically significant delay in gastric emptying.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, liraglutide at 1.2 mg and 1.8 mg per day slows the rate at which food leaves the stomach after eating, resulting in lower blood glucose spikes after meals; a dose of 0.6 mg per day does not slow stomach emptying significantly.
See the scientific wording
In adults with type 2 diabetes, liraglutide at doses of 1.2 and 1.8 mg per day significantly delays gastric emptying during the first hour after a meal, which contributes to reduced postprandial glucose excursions, while the 0.6 mg dose does not produce a statistically significant delay.
Liraglutide binds to receptors in the stomach wall, which reduces the squeezing motion of the lower stomach and tightens the valve at the bottom of the stomach. This slows the movement of food into the small intestine, causing nutrients to enter the bloodstream more slowly and preventing sharp rises in blood sugar after eating.
What the research says
1 studyIn people with type 2 diabetes, higher doses of liraglutide (1.2 mg and 1.8 mg) slow down how fast food leaves the stomach after eating, which helps keep blood sugar from spiking too high—lower doses (0.6 mg) don’t do this as well.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.